Mots-C 40 mg

Overview

MOTS c is a sixteen amino acid mitochondrial derived peptide that links mitochondrial status to whole cell and whole body metabolism. It is used in controlled models to study glucose handling fat metabolism skeletal integrity longevity pathways and cardiovascular function. The sections below summarise how MOTS c is applied in preclinical and translational research. All observations are model specific and do not imply any supplement or therapeutic claims.

1. Muscle metabolism and insulin independent glucose uptake

Mouse studies show that MOTS c can reverse age dependent insulin resistance in skeletal muscle. In these experiments MOTS c improves skeletal muscle response to AMPK activation which increases expression and activity of glucose transporters in myofibers. This effect is largely independent of classical insulin receptor signaling.
That makes MOTS c a useful probe when researchers want to isolate non insulin routes of glucose uptake and examine alternative strategies to support muscle glucose disposal under insulin resistant conditions. Functionally these models report better muscle performance and lower indices of functional insulin resistance after MOTS c exposure.
End points include glucose uptake assays ex vivo force measurements and markers of muscle fiber integrity.

2. Fat metabolism mitochondrial signaling and AMPK

Low estrogen models in mice are used to characterise how hormonal shifts drive increases in fat mass and adipose dysfunction. In these settings MOTS c supplementation increases brown adipose activity reduces total adipose accumulation and limits inflammatory changes in white fat depots that usually precede insulin resistance.
Mechanistic work indicates that MOTS c activates AMPK through upstream effects on the methionine folate cycle and elevation of AICAR a known AMPK activator.
Activated AMPK then enhances uptake and oxidation of both glucose and fatty acids mirroring some of the metabolic patterns seen with ketogenic style diets where fat is preferentially oxidised while lean mass is preserved. Metabolomic profiling in obese mouse models links MOTS c to regulation of sphingolipid monoacylglycerol and dicarboxylate pathways. By down regulating these lipid species and increasing beta oxidation MOTS c helps prevent fat accumulation even under high fat diet conditions.

Newer work shows that under metabolic stress MOTS c moves from mitochondria into the nucleus where it regulates nuclear genes involved in glucose restriction and antioxidant responses. This nuclear action supports a two tier model where MOTS c coordinates mitochondrial and nuclear programs to stabilise energy balance.

3. Insulin sensitivity and early metabolic shifts

Human studies measuring circulating MOTS c levels in lean insulin sensitive and insulin resistant subjects reveal that MOTS c correlates with insulin sensitivity primarily in lean individuals. This pattern suggests that MOTS c changes may be more involved in the early pathogenesis of insulin resistance than in its chronic maintenance.

Researchers are exploring MOTS c as a potential biomarker for early dysregulation in lean people moving toward prediabetes. In parallel mouse work supplementation with MOTS c improves insulin sensitivity markers and delays the onset of overt insulin resistance in high risk models. These data are being used to build early intervention frameworks where MOTS c dynamics could signal when metabolic compensation starts to fail.

4. Bone metabolism and osteoporosis models

MOTS c plays a role in bone anabolism in preclinical models. Osteoblast cell line studies show that MOTS c regulates the TGF beta SMAD pathway which is essential for osteoblast survival and function. By supporting osteoblast viability MOTS c increases synthesis of type I collagen the dominant structural protein in bone.
This translates into improved indicators of bone strength and microarchitecture in experimental systems. Further work in osteoporosis models demonstrates that MOTS c promotes differentiation of bone marrow stem cells into osteoblasts again via TGF beta SMAD signaling. So MOTS c both protects existing bone forming cells and drives their formation from progenitors enhancing osteogenesis in these models.

5. Longevity associated variants and population studies

Genetic research has identified a specific MOTS c sequence variant associated with longevity in certain human populations particularly in Northeast Asia. This variant substitutes a glutamate residue for lysine at position fourteen of the peptide. Because glutamate and lysine possess very different chemical properties this substitution is expected to alter peptide structure and function. Although the precise functional consequences are still under investigation the variant’s enrichment in long lived cohorts has made it a focal point for mitochondrial longevity research. This line of work supports the broader view articulated by investigators such as Changhan David Lee that mitochondrial biology including MDPs like MOTS c may hold key levers for extending both lifespan and healthspan.

6. Cardiovascular and endothelial function

Clinical studies measuring MOTS c levels in patients undergoing coronary angiography show that lower circulating MOTS c is associated with higher indices of endothelial dysfunction. Endothelial cells line blood vessels and control vasodilation coagulation and plaque interaction. Rodent experiments indicate that while MOTS c does not dramatically change baseline vascular reactivity it can sensitise endothelial cells to other vasodilatory signals such as acetylcholine. Supplemented animals show improved endothelial function and better microvascular and epicardial vessel performance in functional tests. In parallel work on mitochondrial derived peptides more broadly at least three MDPs appear to protect cardiac cells from stress and inflammation. Dysregulation of these peptides is being examined as a contributor to cardiovascular disease development reperfusion injury and chronic endothelial dysfunction.

Typical research applications

Across the literature MOTS c is commonly used in skeletal muscle metabolism and insulin resistance models obesity and high fat diet studies focused on fat oxidation and lipid profiles AMPK pathway and methionine folate cycle investigations nuclear gene expression studies following metabolic stress insulin sensitivity biomarker and prediabetes research osteoporosis models examining osteoblast survival and stem cell differentiation longevity and population genetics studies on mitochondrial peptides
cardiovascular and endothelial function research. In all these contexts MOTS c is a mechanistic tool for understanding mitochondrial to nuclear communication and metabolic control not a general purpose metabolic or longevity therapy.

Important research disclaimer

All findings summarised here arise from cell culture systems animal models and limited human observational and interventional studies under defined protocols.
They are provided solely to inform qualified researchers about how MOTS c is used in experimental work. These observations do not show or imply that MOTS c is safe or effective for any human or veterinary indication. They are not dosing instructions medical advice or guidance for weight loss diabetes osteoporosis longevity heart disease or any other condition. MOTS c supplied as a research peptide is intended strictly for educational and scientific research. It is not for human or veterinary use and must not be used for diagnosis treatment cure prevention or mitigation of any disease or condition.